Biologics and Biosimilars Regulations and Registration in South Korea
The Korean pharmaceutical market is estimated to be worth $24.3 billion in 2019, and between 2015 and 2019, it grew […]
Biologics
Registration of Biologics in Malaysia (NPRA)
Biologics have emerged as a significant treatment for various diseases in Malaysia. With their increasing relevance in addressing chronic diseases
Biologics and Biosimilar Regulation and Registration in Japan (PMDA)
With the exception of the United States, Japan’s biosimilar business, with a market value of $140 million, accounted for just
Biosimilars: Affordable and Effective Alternatives to Biologics
Biosimilars are biologic medical products that are highly similar to an already approved reference biologic drug. They are designed to
Biologics and Biosimilars Regulations and Registration in China (NMPA)
In China, 40% of the biologics market comprises biosimilars. The usage of biosimilars in oncology has increased as cancer overtook
New Drugs, Generics and Biosimilars Registration in Singapore: Whitepaper on HSA Regulations
Singapore stands as a beacon of regulatory excellence in the pharmaceutical industry, offering a robust framework that ensures the safety,
Biologics & Biosimilar Regulations in European Union (EU) (EMA)
In 2022, the Europe biosimilar market had a value of almost USD 4601.56 million. In addition, it is anticipated that
Hong Kong: New Drugs, Generics, Biosimilars Regulations
Hong Kong- New Drugs, Generics, Biosimilar Regulations: Hong Kong has a robust regulatory system for pharmaceuticals, overseen by the Department
Biologics and Biosimilars Regulations, Registration Process in the USA (FDA)
The size of the U.S. biosimilars market, estimated at USD 6.73 billion in 2021, is expected to increase by USD